Published in Nat Rev Immunol on April 10, 2012
Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol (2014) 1.03
How can we cure a heart "in flame"? A translational view on inflammation in heart failure. Basic Res Cardiol (2013) 0.94
The immunological synapse. Cancer Immunol Res (2014) 0.93
CD28 Costimulation: From Mechanism to Therapy. Immunity (2016) 0.90
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol (2012) 0.87
T lymphocytes and normal tissue responses to radiation. Front Oncol (2012) 0.86
Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome. Autoimmun Rev (2013) 0.84
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med (2013) 0.84
Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res (2013) 0.84
CD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment? J Immunol Res (2015) 0.83
Human and mouse CD137 have predominantly different binding CRDs to their respective ligands. PLoS One (2014) 0.82
Interleukin-2/Anti-Interleukin-2 Immune Complex Attenuates Cardiac Remodeling after Myocardial Infarction through Expansion of Regulatory T Cells. J Immunol Res (2016) 0.77
Dendritic cells enhance the antigen sensitivity of T cells. Front Immunol (2012) 0.77
Inflammation, obesity, and the promise of immunotherapy for metabolic disease. Surg Obes Relat Dis (2012) 0.77
T-cell costimulatory blockade in organ transplantation. Cold Spring Harb Perspect Med (2013) 0.77
The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology. Br J Clin Pharmacol (2015) 0.76
Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer (2016) 0.76
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One (2016) 0.76
Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. Hum Gene Ther (2015) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Emerging Therapies for Rheumatoid Arthritis. Rheumatol Ther (2016) 0.75
Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice. Sci Rep (2016) 0.75
A Century of Radiation Therapy and Adaptive Immunity. Front Immunol (2017) 0.75
Afterword: returning to philosophical foundations in research ethics. J Med Ethics (2016) 0.75
Ischemic stroke: experimental models and reality. Acta Neuropathol (2017) 0.75
Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative. Ophthalmology (2017) 0.75
[Biologics]. Z Rheumatol (2016) 0.75
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol (2017) 0.75
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature (2002) 2.71
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood (2011) 2.12
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.79
Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol (2003) 1.70
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol (2010) 1.65
Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation (1989) 1.50
CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol (1997) 1.48
Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One (2009) 1.44
Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol (2007) 1.29
Lessons from TGN1412. Lancet (2006) 1.16
Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. J Biol Chem (2008) 1.15
Mitogenic CD28 signals require the exchange factor Vav1 to enhance TCR signaling at the SLP-76-Vav-Itk signalosome. J Immunol (2007) 1.08
Toward experimental assessment of receptor occupancy: TGN1412 revisited. J Allergy Clin Immunol (2008) 0.96